Cognitive behavioral therapy for insomnia (CBT-I) in patients with fibromyalgia: a systematic review and metaanalysis

Purpose: We aimed to evaluate the effectiveness of CBT-i in patients with fibromyalgia in comparison with other non-pharmacological treatments. Methods: Randomized controlled trials assessing the effects of CBT-i in adults with fibromyalgia, published in English or Spanish, were eligible. Electronic...

Descripción completa

Detalles Bibliográficos
Autores: Climent Sanz, Carolina, Valenzuela Pascual, Francesc, Martínez-Navarro, Oriol, Blanco Blanco, Joan, Rubí Carnacea, Francesc, García-Martínez, Ester, Soler González, Jorge, Barallat Gimeno, Eva, Gea Sánchez, Montserrat
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2022
País:España
Institución:Universitat de Lleida (UdL)
Repositorio:Repositori Obert UdL
OAI Identifier:oai:dnet:.___________::8c2c7bb895726bee3b9cf680bae6a38a
Acceso en línea:https://dx.doi.org/10.1080/09638288.2021.1954706
https://hdl.handle.net/10459.1/469859
Access Level:acceso abierto
Palabra clave:Fibromyalgia
Insomnia
Sleep
Poor sleep quality
Cognitive behavioral
Therapy for insomnia
Systematic review
Descripción
Sumario:Purpose: We aimed to evaluate the effectiveness of CBT-i in patients with fibromyalgia in comparison with other non-pharmacological treatments. Methods: Randomized controlled trials assessing the effects of CBT-i in adults with fibromyalgia, published in English or Spanish, were eligible. Electronic searches were performed using PubMed, Scopus, The Cochrane Library, WebOfKnowledge and Psicodoc databases in March 2021. The main outcome measures were sleep efficiency and sleep quality. Secondary outcomes included pain, depression, and anxiety. Results: Of 226 studies reviewed, five were included in the meta-analysis. CBT-i compared with non-pharmacological treatments showed no significant improvements in sleep efficiency (p = 0.05; standardized mean difference (SMD) [95% CI] 0.31 [-0.00 to 0.61]). CBT-i showed significant improvements in sleep quality (p = 0.009; SMD [95% CI] - 0.53 [-0.93 to -0.13]), pain (p = 0.002; SMD [95% CI] - 0.41 [-0.67 to -0.16]), anxiety (p = 0.001; SMD [95% CI] - 0.46 [-0.74 to 0.18]) and depression (p = 0.02; SMD [95% CI] - 0.33 [-0.61 to -0.05]), compared to non-pharmacological treatments. Effect sizes ranged from small to moderate. Conclusions: CBT-i was associated with a significant improvement in sleep quality, pain, anxiety, and depression, although these results are retrieved from very few studies with only very low to low quality evidence. Trial registration: The review protocol was registered with PROSPERO (Record ID ¼ CRD42016030161).